Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy.
Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS, Ahn SH.
Cancer Chemother Pharmacol. 2012 May;69(5):1221-7. Epub 2012 Jan 20.
Related citations
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.
Walko CM, Combest AJ, Spasojevic I, Yu AY, Bhushan S, Hull JH, Hoskins J, Armstrong D, Carey L, Collicio F, Dees EC.
Cancer Chemother Pharmacol. 2012 May;69(5):1189-96. Epub 2012 Jan 15.
Gene therapy with RNAi targeting UHRF1 driven by tumor-specific promoter inhibits tumor growth and enhances the sensitivity of chemotherapeutic drug in breast cancer in vitro and in vivo.
Fang L, Shanqu L, Ping G, Ting H, Xi W, Ke D, Min L, Junxia W, Huizhong Z.
Cancer Chemother Pharmacol. 2012 Apr;69(4):1079-87. Epub 2011 Dec 29.
Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K, Mitomi H, Alkam Y, Arakawa A, Yao T, Tokuda E, Saito M, Kasumi F.
Cancer Chemother Pharmacol. 2012 Apr;69(4):923-30. Epub 2011 Nov 15.
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M, Isambert N, Bourbouloux E, Roché H, Bonneterre J, Milano G, Fumoleau P.
Cancer Chemother Pharmacol. 2012 Apr;69(4):871-9. Epub 2011 Nov 2.
Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis.
Lombardi G, Nicoletto MO, Gusella M, Fiduccia P, Dalla Palma M, Zuin A, Fiore D, Donach M, Zagonel V.
Cancer Chemother Pharmacol. 2012 Mar;69(3):781-7. Epub 2011 Oct 29.
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z, Lu J, Leaw S, Hong X, Wang J, Shao Z, Hu X.
Cancer Chemother Pharmacol. 2012 Feb;69(2):515-22. Epub 2011 Aug 27.
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Ando M, Yonemori K, Katsumata N, Shimizu C, Hirata T, Yamamoto H, Hashimoto K, Yunokawa M, Tamura K, Fujiwara Y.
Cancer Chemother Pharmacol. 2012 Feb;69(2):457-65. Epub 2011 Aug 19.
The marine sponge toxin agelasine B increases the intracellular Ca(2+) concentration and induces apoptosis in human breast cancer cells (MCF-7).
Pimentel AA, Felibertt P, Sojo F, Colman L, Mayora A, Silva ML, Rojas H, Dipolo R, Suarez AI, Compagnone RS, Arvelo F, Galindo-Castro I, De Sanctis JB, Chirino P, Benaim G.
Cancer Chemother Pharmacol. 2012 Jan;69(1):71-83. Epub 2011 May 21.
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D.
Cancer Chemother Pharmacol. 2012 Jan;69(1):35-42. Epub 2011 May 18.
Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
Rezai K, Urien S, Isambert N, Roche H, Dieras V, Berille J, Bonneterre J, Brain E, Lokiec F.
Cancer Chemother Pharmacol. 2011 Dec;68(6):1529-36. Epub 2011 Apr 26.
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.
Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD.
Cancer Chemother Pharmacol. 2011 Aug;68(2):547-52. Epub 2011 Apr 24.
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Frances N, Claret L, Bruno R, Iliadis A.
Cancer Chemother Pharmacol. 2011 Dec;68(6):1413-9. Epub 2011 Apr 8.
Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW, Zhu GY, Shen XL, Chu JH, Yu ZL, Fong WF.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1315-23. Epub 2011 Apr 3.
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Park IH, Lee YS, Lee KS, Kim SY, Hong SH, Jeong J, Lee H, Ro J, Nam BH.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1263-71. Epub 2011 Mar 27.
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells.
Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L.
Cancer Chemother Pharmacol. 2011 Nov;68(5):1161-72. Epub 2011 Mar 13.
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Murialdo R, Bertolotti F, Pastorino G, Mencoboni M, Bergaglio M, Folco U, Cinzia N, Vaira F, Simoni C, Canobbio L, Parodi M, Brema F, Ballestrero A.
Cancer Chemother Pharmacol. 2011 Oct;68(4):1009-16. Epub 2011 Feb 16.
Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer.
Fernandes BJ, Silva Cde M, Andrade JM, Matthes Ado C, Coelho EB, Lanchote VL.
Cancer Chemother Pharmacol. 2011 Oct;68(4):897-904. Epub 2011 Feb 3.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on